Gustave Roussy partners with One Biosciences, a techbio company that harnesses single cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate ...

In cases of metastatic pancreatic tumors, daraxonrasib has been shown to drastically increase survival rates, according to an ...

Cancer (the overall name given to >200 different diseases characterized by out-of-control cell growth) is second only to cardiovascular disease as a major cause of death worldwide. While overall ...

The partnership will leverage Gustave Roussy’s cancer research excellence and Sofinnova’s five decades of experience investing in early-stage innovation in the life sciences PARIS--(BUSINESS ...

Partnership will leverage Gustave Roussy’s tumor samples and Veracyte’s Biopharma Atlas multi-omic database and machine learning capabilities Through the partnership, Gustave Roussy’s Department of ...

To mark the 150th anniversary of its founder’s birth and the upcoming centennial of the Institute that bears his name, Gustave Roussy is proud to announce the launch of the Gustave Roussy Prize. This ...

Gray, developer of the GrayOS care orchestration platform, announced last week during ESTRO the deployment of its solution at Gustave Roussy, the leading cancer ...

Newly created spin-off of Gustave Roussy and SATT Paris-Saclay specializing in immuno-oncology will exploit hidden genome, also known as dark genome or non-coding genome It intends to develop a first ...

PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of ...

FT. LAUDERDALE, Fla. and PARIS, January 12. Anju Software announced that Gustave Roussy, one of the top five cancer research centers in the world and Europe's top-ranked hospital for oncology research ...